The Surprising Reason This Biotech Just Plummeted 67% - Investor's Business Daily

The Surprising Reason This Biotech Just Plummeted 67% Investor's Business Daily Eyepoint study results for vision treatment disappoint, but company still sees promise STAT EyePoint's drug for age-related eye disease fails late-stage trial, shares tank Reuters EYPT Stock On Track To Hit 16-Month Lows After Wet AMD Trial Setback – Retail Sees Ocular Therapeutics As A Better Buyout Candidate…